Skip to main content

Table 1 Services offered in the ANC among attending women Asembo/Gem 2005 and 2002.

From: Antenatal and delivery care in rural western Kenya: the effect of training health care workers to provide "focused antenatal care"

  Asembo 2005 Gem 2005 Asembo 2002 Gem 2002
Services n (%) n (%) n (%) n (%)
Palpation of abdomen 238/241 (98.8) 381/384 (99.2) 290/292 (99.3) 272/278 (97.8)
Listen to foetal heart rate 233/241 (96.7) 377/384 (98.2) NA NA
Tetanus vaccination 232/242 (95.9) 361/382 (94.5) 282/292 (96.6) 273/278 (98.2)
Weight measurement 191/241 (79.3)* 377/384 (98.2) 241/293 (82.3)* 277/278 (99.6)
Iron supplementation 197/239 (82.4)* 260/373 (69.7) 154/289 (53.3) 149/277 (53.8)
Folic acid supplementation 167/232 (72.0)* 170/356 (47.8) 153/290 (52.8)* 100/269 (37.2)
SP ≥ 1 dose 148/240 (61.7)* 74/373 (19.8) 58/286 (20.3) 63/277 (22.7)
SP ≥ 2 doses 67/237 (28.3)* 14/370 (3.8) 22/237 (9.3) 20/357 (5.6)
Blood pressure measurement 152/240 (63.3)* 274/384 (71.4) 198/292 (67.8) 187/276 (67.8)
Test haemoglobin level 72/237 (30.8) 144/377 (38.2) 148/286 (51.8) 138/274 (48.5)
Urine analysis done 73/240 (30.4)* 88/383 (23.0) 59/293 (20.1)* 30/278 (10.8)
Stool test 58/240 (24.2)* 45/384 (11.7) 50/293 (17.1)* 22/278 (7.9)
Antihelminth treatment 30/237 (12.7)* 15/365 (4.1) 13/283 (4.6)* 2/268 (0.8)
Offered test for STD (e.g. syphilis) 20/232 (8.6) 45/377 (11.9) 62/289 (21.5) 49/277 (17.7)
Offered test for HIV 26/232 (11.2)* 139/379 (36.7) NA NA
Health talk provided 42/240 (17.5)* 115/382 (30.1) 45/289 (15.6) 35/278 (12.6)
Information provided on:     
   Danger signs in pregnancy 25/241 (10.4) 44/376 (11.7) 49/291 (16.8) 33/276 (12.0)
   Malaria in pregnancy 58/241 (24.0) 83/381 (21.8) NA NA
   Birth plan discussed 33/241 (13.7)* 80/380 (21.1) NA NA
   Danger signs during delivery 17/241 (7.1) 37/380 (9.7) NA NA
   Danger signs after delivery 11/240 (4.6) 33/381 (8.7) NA NA
   Breastfeeding 36/240 (15.0)* 85/383 (22.2) NA NA
   Family planning 18/240 (7.5)* 97/383 (25.3) NA NA
  1. NA: Not Available SP: sulfadoxine-pyrimethamine
  2. * p < 0.05 comparing areas in the same survey